{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:19:10Z","timestamp":1795112350755,"version":"4.10.3"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Systemic JIA (sJIA), a multifaceted autoinflammatory disorder, can be complicated by life-threatening conditions such as macrophage activation syndrome (MAS) and interstitial lung disease. The management of these conditions presents a therapeutic challenge, underscoring the need for innovative treatment approaches.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To report the possible role of MAS825, a bispecific anti-IL1\u03b2 and IL-18 monoclonal antibody, in the treatment of multi-drug-resistant sJIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report two patients affected by sJIA with severe and refractory MAS and high serum IL-18 levels, responding to dual blockade of IL-1\u03b2 and IL-18.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The first patient is a 20-year-old man, presenting a severe MAS complicated by thrombotic microangiopathy, following SARS-CoV-2 infection. He was treated with MAS825, with quick improvement. Eighteen months later, the patient is still undergoing biweekly treatment with MAS825, associated with MTX, ciclosporin and low-dose glucocorticoids, maintaining good control over the systemic features of the disease. The second patient, a 10-year-old girl, presented a severe MAS case, complicated by posterior reversible encephalopathy syndrome, following an otomastoiditis. The MAS was not fully controlled despite treatment with i.v. high-dose glucocorticoids, anakinra and ciclosporin. She began biweekly MAS825, which led to a prompt amelioration of MAS parameters. After 10\u2009months, the patient continues to receive MAS825 and is in complete remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In light of the pivotal role of IL-1\u03b2 and IL-18 in sJIA, MAS and interstitial lung disease, MAS825 might represent a possible valid and safe option in the treatment of drug-resistant sJIA, especially in the presence of high serum IL-18 levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae440","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:18:40Z","timestamp":1724458720000},"page":"1528-1533","source":"Crossref","is-referenced-by-count":25,"title":["Long-term efficacy of MAS825, a bispecific anti-IL1\u03b2 and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndrome"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-7846","authenticated-orcid":false,"given":"Roberta","family":"Caorsi","sequence":"first","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]},{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arinna","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-0569","authenticated-orcid":false,"given":"Caterina","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]},{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Natoli","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]},{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Palmeri","sequence":"additional","affiliation":[{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rosina","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Penco","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Malattia","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]},{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]},{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Viola","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-5470","authenticated-orcid":false,"given":"Riccardo","family":"Papa","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Corcione","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpi","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]},{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Universit\u00e0 degli Studi di Genova , Genova,","place":["Italy"]},{"name":"Scientific Direction, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-1916","authenticated-orcid":false,"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[{"name":"Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini , Genova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"2025030500190019800_keae440-B1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","article-title":"Macrophage activation syndrome","volume":"29","author":"Ravelli","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025030500190019800_keae440-B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500190019800_keae440-B3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"2025030500190019800_keae440-B4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030500190019800_keae440-B5","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.26091","article-title":"Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis","volume":"96","author":"Boonstra","year":"2021","journal-title":"Am J Hematol"},{"key":"2025030500190019800_keae440-B6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030500190019800_keae440-B7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3390\/genes12091299","article-title":"Targeted NGS yields plentiful ultra-rare variants in inborn errors of immunity patients","volume":"12","author":"Grossi","year":"2021","journal-title":"Genes (Basel)"},{"key":"2025030500190019800_keae440-B8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12969-020-00450-9","article-title":"Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases","volume":"18","author":"Papa","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025030500190019800_keae440-B9","doi-asserted-by":"crossref","first-page":"ofae369","DOI":"10.1093\/ofid\/ofae369","article-title":"Therapeutic role of HPV-vaccination on benign HPV-induced epithelial proliferations in immunocompetent and immunocompromised patients: case study and review of the literature","volume":"11","author":"Matucci-Cerinic","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025030500190019800_keae440-B10","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025030500190019800_keae440-B11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500190019800_keae440-B12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025030500190019800_keae440-B13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025030500190019800_keae440-B14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cei\/uxad065","article-title":"Efficacy and safety of MAS825 (anti-IL-1\u03b2\/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function","volume":"213","author":"Hakim","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2025030500190019800_keae440-B15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","article-title":"Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1\u03b2 and IL-18","volume":"43","author":"Rood","year":"2023","journal-title":"J Clin Immunol"},{"key":"2025030500190019800_keae440-B16","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1093\/rheumatology\/kead612","article-title":"Experience of anti IL-1\u03b2 and anti IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome","volume":"63","author":"\u00c7a\u011flayan","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500190019800_keae440-B17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jpeds.2021.04.004","article-title":"Thrombotic microangiopathy associated with macrophage activation syndrome: a multinational study of 23 patients","volume":"235","author":"Minoia","year":"2021","journal-title":"J Pediatr"},{"key":"2025030500190019800_keae440-B18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025030500190019800_keae440-B19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae440\/59067297\/keae440.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1528\/59067297\/keae440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1528\/59067297\/keae440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:22:58Z","timestamp":1741134178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1528\/7739895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,23]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae440","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,8,23]]}}}